Immunic Strengthens Leadership with Jaa Roberson's Appointment as Chief People Officer

Immunic Appoints Jaa Roberson as Chief People Officer

Immunic, Inc., a prominent late-stage biotechnology firm, recently made headlines with the strategic appointment of Jaa Roberson as its new Chief People Officer (CPO). This decision aims to bolster the company’s leadership, particularly as it gears up for advancing the development of its innovative oral therapies for neurologic diseases, primarily focusing on multiple sclerosis (MS).

A Key Move for Immunic

Effective immediately, Ms. Roberson will report directly to Immunic's Chief Executive Officer, Erik Lundgren, and will play a crucial role on the executive leadership team. This newly established position is set to enhance the company’s overall talent acquisition and organizational strategy, necessary for securing specialized skills as they approach pivotal milestones, including a significant Phase 3 clinical trial by the end of 2026 and the potential commercialization of vidofludimus calcium (IMU-838).

Lundgren expressed his enthusiasm for Roberson's inclusion, stating, “Over the past several months, we have been assembling a leadership team with extensive MS experience. Jaa's addition aligns with our goal of building an exceptional MS organization at a critical time when we anticipate pivotal data in relapsing MS.” He emphasized that Roberson's strategic partnership will be vital in attracting and retaining top talent, establishing a solid organizational culture to transition from a research-focused entity to a fully integrated commercial organization.

Jaa Roberson's Background

Jaa Roberson is no stranger to human resources, with over 20 years of experience across various sectors including biopharma, health insurance, and retail. Before joining Immunic, she served as the Chief People Officer at Day One Biopharmaceuticals, where she played an instrumental role in scaling the organization from 37 to 200 employees while maintaining high engagement levels. Her previous positions at companies like Bellicum Pharmaceuticals and Achaogen saw her lead HR efforts during expansions and transitions, reinforcing her capabilities in nurturing a thriving workforce.

Roberson's tenure at Genentech allowed her to support the development of MS-related therapeutics among other critical projects. Holding a Bachelor of Arts from Rice University and a Master of Music in Violin Performance from the San Francisco Conservatory of Music, Roberson has an impressive arsenal of skills to draw upon as she steps into her role at Immunic.

Looking Ahead

As Immunic prepares for the expected top-line data from their Phase 3 clinical trials, Roberson’s focus will be on fostering the organization's growth. Her ambitions include enhancing the talent pool and capabilities necessary to facilitate regulatory approval and commercialization initiatives, while simultaneously preserving the company’s agility that is fundamental to its biotechnology ethos. “I am thrilled to join Immunic at such a pivotal moment,” Roberson noted, emphasizing her commitment to building a high-performing and inclusive workplace that can contribute significantly to patient outcomes.

Immunic's Vision

Immunic is known for its pioneering work in creating novel oral therapies that address neurological issues. The lead candidate, vidofludimus calcium, is currently undergoing critical evaluations within Phase 3 clinical trials for relapsing forms of MS, with results anticipated by the end of 2026. This innovation is positioned to combine neuroprotective benefits and anti-inflammatory effects, thereby emphasizing the company’s commitment to addressing challenging health conditions through scientific advancements.

The company is steadily building a pipeline that includes additional therapeutic programs aimed at neurodegenerative and autoimmune disorders, reinforcing its strategy of advancing healthcare through cutting-edge biotechnology. As Immunic continues its journey, the appointment of Jaa Roberson serves as a testament to its determination to cultivate exemplary leadership and harness specialized talent that will propel its mission forward.